Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) – Pipeline Review, H2 2016’, provides in depth analysis on Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1)

The report reviews Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

AbbVie Inc

Amgen Inc

Astex Pharmaceuticals Inc

CASI Pharmaceuticals Inc

Cielo Therapeutics Inc

Merck & Co Inc

Millennium Pharmaceuticals Inc

Sanofi

Sareum Holdings Plc

Sigma-Tau SpA

Taiho Pharmaceutical Co Ltd

Vertex Pharmaceuticals Inc

Vichem Chemie Research Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC

2.7.11.1) Overview 8

Therapeutics Development 9

Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC

2.7.11.1) - Products under Development by Stage of Development 9

Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC

2.7.11.1) - Products under Development by Therapy Area 10

Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC

2.7.11.1) - Products under Development by Indication 11

Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC

2.7.11.1) - Pipeline Products Glance 13

Late Stage Products 13

Early Stage Products 14

Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC

2.7.11.1) - Products under Development by Companies 15

Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC

2.7.11.1) - Products under Development by Universities/Institutes 19

Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC

2.7.11.1) - Therapeutics Assessment 21

Assessment by Monotherapy/Combination Products 21

Assessment by Mechanism of Action 22

Assessment by Route of Administration 23

Assessment by Molecule Type 25

Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC

2.7.11.1) - Companies Involved in Therapeutics Development 26

AbbVie Inc 26

Amgen Inc 27

Astex Pharmaceuticals Inc 28

CASI Pharmaceuticals Inc 29

Cielo Therapeutics Inc 30

Merck & Co Inc 31

Millennium Pharmaceuticals Inc 32

Sanofi 33

Sareum Holdings Plc 34

Sigma-Tau SpA 35

Taiho Pharmaceutical Co Ltd 36

Vertex Pharmaceuticals Inc 37

Vichem Chemie Research Ltd 38

Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC

2.7.11.1) - Drug Profiles 39

alisertib - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

AMG-900 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

AT-9283 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

danusertib - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

ENMD-2076 - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

ilorasertib - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

MK-8745 - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

SAR-156497 - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

SAR-3 - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

SAR-4 - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

Small Molecule to Inhibit Aurora A Kinase for Oncology - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

Small Molecule to Inhibit Aurora A Kinase for Oncology - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

Small Molecules to Inhibit Aurora A Kinase for Oncology - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

Small Molecules to Inhibit Aurora A/B Kinase for Oncology - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

ST-5589 - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

TAS-119 - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

VE-465 - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC

2.7.11.1) - Dormant Projects 68

Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC

2.7.11.1) - Discontinued Products 77

Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC

2.7.11.1) - Featured News & Press Releases 79

Aug 16, 2016: CASI Pharmaceuticals Provides Update On Phase 2 Trial Of ENMD-2076 In Fibrolamellar Carcinoma 79

Aug 03, 2016: China and Hong Kong Patent Grants for Sareum’s Aurora+FLT3 Kinase Inhibitors 79

Jun 01, 2016: CASI Pharmaceuticals Announces Poster Presentation At ASCO On ENMD-2076 In Patients With Ovarian Clear Cell Carcinoma 80

May 12, 2016: CASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase 2 Clinical Trial With ENMD-2076 For Fibrolamellar Carcinoma (FLC) 80

Nov 08, 2015: Data On Anti-Tumor Activity Of ENMD-2076 In Triple Negative Breast Cancer Animal Models Presented In Poster Session At AACR-NCI-EORTC International Conference 80

Nov 05, 2015: Poster For ENMD-2076 Phase 2 Trial In Soft Tissue Sarcoma Presented At The 2015 Connective Tissue Oncology Society Annual Meeting 81

Nov 04, 2015: CASI Pharmaceuticals Announces First Patient Dosed In Phase 2 Trial For ENMD-2076 In Fibrolamellar Carcinoma 82

Oct 14, 2015: CASI Pharmaceuticals Receives EU Orphan Drug Designation For The Use Of ENMD-2076 To Treat Hepatocellular Carcinoma Including Fibrolamellar Carcinoma 83

Sep 15, 2015: US and European Patent Grants for Sareum's Aurora+FLT3 Kinase Inhibitors 83

Jun 04, 2015: CASI Files New Drug Clinical Trial Application With China FDA To Expand U.S. Development Of ENMD-2076 In Fibrolamellar Carcinoma 84

May 12, 2015: Takeda Announces Termination of Alisertib Phase 3 Trial in Relapsed or Refractory Peripheral T-cell Lymphoma 84

Mar 30, 2015: CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 85

Mar 25, 2015: CASI Pharmaceuticals Announces Initiation Of A Phase 2 Trial With ENMD-2076 In Triple-Negative Breast Cancer In China 85

Feb 09, 2015: CASI Pharmaceuticals Announces Receipt Of Final Minutes From FDA Meeting Regarding Clinical And Regulatory Path Of ENMD-2076 For Fibrolamellar Carcinoma 86

Dec 17, 2014: CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 87

Appendix 88

Methodology 88

Coverage 88

Secondary Research 88

Primary Research 88

Expert Panel Validation 88

Contact Us 88

Disclaimer 89

List of Tables

List of Tables

Number of Products under Development for, H2 2016 9

Number of Products under Development by Therapy Area, H2 2016 10

Number of Products under Development by Indication, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 13

Comparative Analysis by Early Stage Products, H2 2016 14

Number of Products under Development by Companies, H2 2016 15

Products under Development by Companies, H2 2016 16

Products under Development by Companies, H2 2016 (Contd..1) 17

Products under Development by Companies, H2 2016 (Contd..2) 18

Number of Products under Investigation by Universities/Institutes, H2 2016 19

Products under Investigation by Universities/Institutes, H2 2016 20

Assessment by Monotherapy/Combination Products, H2 2016 21

Number of Products by Stage and Mechanism of Action, H2 2016 22

Number of Products by Stage and Route of Administration, H2 2016 24

Number of Products by Stage and Molecule Type, H2 2016 25

Pipeline by AbbVie Inc, H2 2016 26

Pipeline by Amgen Inc, H2 2016 27

Pipeline by Astex Pharmaceuticals Inc, H2 2016 28

Pipeline by CASI Pharmaceuticals Inc, H2 2016 29

Pipeline by Cielo Therapeutics Inc, H2 2016 30

Pipeline by Merck & Co Inc, H2 2016 31

Pipeline by Millennium Pharmaceuticals Inc, H2 2016 32

Pipeline by Sanofi, H2 2016 33

Pipeline by Sareum Holdings Plc, H2 2016 34

Pipeline by Sigma-Tau SpA, H2 2016 35

Pipeline by Taiho Pharmaceutical Co Ltd, H2 2016 36

Pipeline by Vertex Pharmaceuticals Inc, H2 2016 37

Pipeline by Vichem Chemie Research Ltd, H2 2016 38

Dormant Projects, H2 2016 68

Dormant Projects (Contd..1), H2 2016 69

Dormant Projects (Contd..2), H2 2016 70

Dormant Projects (Contd..3), H2 2016 71

Dormant Projects (Contd..4), H2 2016 72

Dormant Projects (Contd..5), H2 2016 73

Dormant Projects (Contd..6), H2 2016 74

Dormant Projects (Contd..7), H2 2016 75

Dormant Projects (Contd..8), H2 2016 76

Discontinued Products, H2 2016 77

Discontinued Products (Contd..1), H2 2016 78

List of Figures

List of Figures

Number of Products under Development for, H2 2016 9

Number of Products under Development by Top 10 Indication, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 14

Assessment by Monotherapy/Combination Products, H2 2016 21

Number of Products by Stage and Mechanism of Actions, H2 2016 22

Number of Products by Routes of Administration, H2 2016 23

Number of Products by Stage and Routes of Administration, H2 2016 23

Number of Products by Stage and Molecule Type, H2 2016 25

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports